The DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Diabetes and Hypertension: A Position Statement by the American Diabetes Association
Open accessAbstract
Hypertension is common among patients with diabetes, with the prevalence depending on type and duration of diabetes, age, sex, race/ethnicity, BMI, history of glycemic control, and the presence of kidney disease, among other factors (1-3).Furthermore, hypertension is a strong risk factor for atherosclerotic cardiovascular disease (ASCVD), heart failure, and microvascular complications.ASCVDddefined as acute coronary syndrome, myocardial infarction (MI), angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease presumed to be of atherosclerotic origindis the leading cause of morbidity and mortality for individuals with diabetes and is the largest contributor to the direct and indirect costs of diabetes.Numerous studies have shown that antihypertensive therapy reduces ASCVD events, heart failure, and microvascular complications in people with diabetes (4-8).Large benefits are seen when multiple risk factors are addressed simultaneously (9).There is evidence that ASCVD morbidity and mortality have decreased for people with diabetes since 1990 (10,11) likely due in large part to improvements in blood pressure control (12-14).This Position Statement is intended to update the assessment and treatment of hypertension among people with diabetes, including advances in care since the American Diabetes Association (ADA) last published a Position Statement on this topic in 2003 (3). DEFINITIONS, SCREENING, AND DIAGNOSISRecommendations c Blood pressure should be measured at every routine clinical care visit.Patients found to have an elevated blood pressure ($140/90 mmHg) should have blood pressure confirmed using multiple readings, including measurements on a separate day, to diagnose hypertension.B c All hypertensive patients with diabetes should have home blood pressure monitored to identify white-coat hypertension.B c Orthostatic measurement of blood pressure should be performed during initial evaluation of hypertension and periodically at follow-up, or when symptoms of orthostatic hypotension are present, and regularly if orthostatic hypotension has been diagnosed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is strong evidence from clinical trials of the value of treating hypertension in older adults (70,71), with treatment of hypertension to individualized target levels indicated in most.”
From 13. Older Adults: Standards of Care in Diabetes—2024 (2024) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is strong evidence from clinical trials of the value of treating hypertension in older adults (72,73), with treatment of hypertension to individualized target levels indicated in most.”
From 13. Older Adults: Standards of Care in Diabetes—2025 (2025) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is strong evidence from clinical trials of the value of treating hypertension in older adults”
From 13. Older Adults: Standards of Care in Diabetes—2026 (2026) · cites this paper as [80]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [70]
The cited source says what the claim attributes to it.
In the citing paper
“For individuals with albuminuria (urine albumin-to-creatinine ratio [UACR] $30 mg/g), initial treatment should include an ACE inhibitor or ARB to reduce the risk of progressive kidney disease (21) (Fig. 10.2).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [21]
In the citing paper
“For patients with albuminuria (urine albumin-to-creatinine ratio [UACR] $ 30 mg/g), initial treatment should include an ACE inhibitor or ARB to reduce the risk of progressive kidney disease (20) ( Fig. 10.2 ).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Sacks, F. M., Svetkey, L. P., Vollmer, W. M., Appel, L. J., Bray, G. A., Harsha, D., Obarzanek, E., Conlin, P. R., Miller, E. R., Simons-Morton, D. G., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101043440101 · Cited by 5,638
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Flagged first, then by citations
Research works printed but not linked: 1
- Lin JS, O’Connor EA, Evans CV, Senger CA, Rowland MG, Groom HC. Behavioral Counseling to Promote a Healthy Lifestyle for Cardiovascular Disease Prevention in Persons With Cardiovascular Risk Factors: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet], 2014. Rockville, MD, Agency for Healthcare Research and Quality (US), 2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK241537/. Accessed 11 November 2016
Cited by
Sorted by citations
Items 701–714 of 714
Allahdadi, A., Golestani, A., Djalalinia, S., Mohseni, S., Sani, M. P., & Tabatabaei‐Malazy, O. (2026) · Research Square · doi:10.21203/rs.3.rs-9459775/v1
Cardio–kidney–metabolic syndrome: Underutilized screening and management in primary care settings
Zayan, T. A., & Khafagy, H. A. (2026) · World Advances in Renal Medicine · doi:10.25259/warm_24_2025
Izadi, N., Ehtemami, A., Haghighi, S. O., Amirroud, M. M., Azizi, F., & Amiri, P. (2026) · Research Square · doi:10.21203/rs.3.rs-9717641/v1
Yaşar, S., Anderson, A., Hayden, K. M., Carmichael, O. T., Clark, J. M., Carlson, M. C., Asby, D. J., Kehoe, P. G., Miners, J. S., & Espeland, M. A. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261458824
Claudel, S. E., & Verma, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71059
Augmenting individualized treatment planning via data-driven clinical role model selection
Liao, C.-Y., Keyvanshokooh, E., Pasquel, F. J., & Garcia, G. P. (2026) · Production and Operations Management · doi:10.1177/10591478261470667
Correlation of Isolated Masked Nocturnal Hypertension with Retinopathy in Diabetic Patients
Mustafa, H. M., Mahwi, T., & Rashid, Z. G. (2026) · Al-Rafidain Journal of Medical Sciences · doi:10.54133/ajms.v11i1.3129
Abas, M. Z., Zaidi, N. A. M., Lee, P. J., Teh, X. R., Wan, K. S., Samad, A. A., Chan, H., Sivasampu, S., & Ang, S. H. (2026) · PLoS ONE · doi:10.1371/journal.pone.0355227
Hsu, W.-C., Hung, S., Lin, S.-H., Chiou, Y., Lin, Y., Wang, H.-H., Ho, L., & Lee, Y. (2026) · Renal Failure · doi:10.1080/0886022x.2026.2711459
Afrifa‐Yamoah, E. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70064
Blood pressure targets for hypertension in people with diabetes mellitus
Larvie, D. Y., Ambasta, A., Jauca, C. D., Salzwedel, D. M., Wright, J., Grenet, G., Fuller, C., & Thompson, W. (2026) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd016392
Mitha, K., V, Smruthi, V., & Paul, P. (2026) · Cureus · doi:10.7759/cureus.117106
Fan, H., Zhai, C., He, C., Shen, L., Pan, H. Y., & Zheng, W. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm50762
Diretriz Brasileira de Cardiogeriatria – 2026
Helber, I., Zanon, J. C. D. C., Peixoto, J. M., Caixeta, A. M., Nussbacher, A., de Oliveira, D. C., de Freitas, E. V., Cintra, F. D., Garcia, J. S., Miranda, R. D., et al. (2026) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20260795
Metadata
- Authors
- de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S., & Bakris, G.
- Affiliations
- University of Washington, Seattle, WA
- New York University (US)
- Université de Lorraine, Nancy, France
- University of Chicago (US)
- Johns Hopkins University (US)
- University of Alabama at Birmingham (US)
- University of Copenhagen (DK)
- Monash University (AU)
- Corresponding author
- Bakris, George
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-08-14
- Volume
- 40
- Issue
- 9
- Pages
- 1273-1284
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2748201042
- Semantic Scholar
- 4e3c7fd3bbe3119a559b61514192347b33e3e619
- Cited by
- 714
- References
- 145
- Citations by year
- 2026: 30 · 2025: 67 · 2024: 89 · 2023: 69 · 2022: 102 · 2021: 113 · 2020: 83 · 2019: 81 · 2018: 71 · 2017: 5
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, other-oa)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Ironwood Pharmaceuticals, Incorporated
- Medicines Company
- Steno Diabetes Center Copenhagen (SDCC 3.A Complications)
- Novo Nordisk
- Astellas Pharma
- Novo Nordisk Fonden (NNF14OC0013659)
- Servier
- Sanofi Australia
- Abbott Vascular
- Defense Acquisition Program Administration
- Relypsa
- National Heart, Lung, and Blood Institute
- Cilag
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- hypertension, diabetes mellitus, atherosclerotic cardiovascular disease, heart failure, microvascular complications, antihypertensive therapy, blood pressure screening, home blood pressure monitoring, white coat hypertension, orthostatic hypotension, blood pressure control, risk factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
